Juan Ignacio Diddi – General Manager, BMS Puerto Rico & Caribbean
Juan Ignacio Diddi, GM of BMS Puerto Rico & Caribbean, has over 20 years of experience in the pharmaceutical industry, having held various roles across Latin America before taking on…
Address: Avenue Provinciale, 30
1340 Louvain-la-Neuve
Belgium
Tel: +32 (0)10 61 44 44
Web: http://www.iddi.com/
IDDI’s business is that of a eClinical and Biostatistical services provider for clinical trials since 1991. IDDI’s mission is to optimize the clinical development of drugs, biologics and devices, using a unique combination of advanced biostatistics and innovative data management technology.
Services:
Innovative trial design
Biostatistics: expert statistical analyses, validation of biomarkers, support to IDMC
Cost effective Data management and Electronic Data Capture
Professional Medical writing
eClinical Suite
IWRS / IVRS : ID-net™, a centralized randomization system integrated with EDC.
ID-supply™ , a drug inventory and treatment allocation system.
ID-code™, a coding of medical terms system based onMedDRA® and WHO-DRUG dictionaries.TrialControl™, a secure eRoom portal to access to key trial data and documents.
Juan Ignacio Diddi, GM of BMS Puerto Rico & Caribbean, has over 20 years of experience in the pharmaceutical industry, having held various roles across Latin America before taking on…
Giddi Pharma was founded in 1995. What was the vision behind the creation of the company? What founding principles did you have when you founded Giddi? When I founded this…
Rainer Westermann offers a sobering take on Europe’s declining global status as both a source and recipient of biopharmaceutical innovation. He argues that the time for a paradigm shift in…
Writing in the January 2026 edition of DIA’s Global Forum, Samantha Holmes and Fiona Adshead of the Sustainable Healthcare Coalition argue that climate change is already reshaping healthcare and the…
The EU’s Health Technology Assessment Regulation (HTAR), which kicked off in January 2025, has launched joint clinical assessments (JCAs) for oncology and advanced therapies; yet six months in, implementation remains…
The latest stories from healthcare and the life sciences in Belgium, the Netherlands and Luxembourg (BeNeLux). UCB is considering a USD five billion investment in the US to avoid President…
Lora Fleifel, Director of Global Value Access & Pricing Operations Europe for Oncology at Merck, dissects the promise and pitfalls of the new EU Joint Clinical Assessment (JCA). The JCA…
To address the European Union’s drop in global share of clinical trials over the past decade, stakeholders are working together to deliver a dynamic, agile, responsive EU clinical trials environment.…
Will a new ‘Critical Medicines Act’ go far enough to ensure Europe’s resilience to future health crises? A Continent at Risk The COVID-19 pandemic exposed serious vulnerabilities in the…
The EMA’s Pre-Accession Assistance Program (IPA) helps EU candidate and potential candidate countries align their medicines regulations with EU standards through training, capacity-building, and policy support. As a new op-ed…
The European Brain Council (EBC) is a key player in advancing brain health research and policy across Europe, bringing together diverse voices to address the pressing issues of neurological and…
James Riddle of Advarra, writing in the January 2025 edition of DIA’s Global Forum magazine, looks at how the EU’s AI Regulation will impact clinical trials in Europe. In…
Last year the European Commission (EC) came out with a proposal to reform the EU’s core pharmaceutical legislation, aiming to address affordability, accessibility, and availability, among other objectives. One of…
Vikas Krishan, chief digital business officer at the global data and digital engineering solutions firm Altimetrik, outlines the implications of the European Union’s forthcoming AI Act for the pharma industry…
See our Cookie Privacy Policy Here
